I'm a paragraph. Click here to add your own text​

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Our team

Pharmetheus consultants and advisors present a unique collection of experiences and combination of skill sets.

Agneta Franksson

Board Member

  • Holds a MBA from Uppsala University and a Master of Science degree from the Royal institute of Technology in Stockholm (electrical and biomedical engineering).
  • Experience from two CEO positions, Vita Nova Ventures AB (Publ) (a CRO company) and Falck Ambulans AB (healthcare services) and more than 25 years’ experience from research, clinical trials, product/service development, and international complex sales and marketing.
  • Since 2006 she runs her own management consulting firm focusing on analytic work, developing road maps, strategic plans, project managements, brand, profile, value work, and implementation of market access strategies.
  • Has served on several boards of directors during the last 12 years. Today she is a member of the board of Blekinge Institute of Technology and Arocell AB (Publ.) and serves as the Chairman of the Board of Directors of Specialplast Wensbo AB, Earlabs AB and HoofStep AB.
  • Received the national prize “Supergasell 2016” (Dagens Industri).
Dr. Anders Kristoffersson, Consultant

Dr. Anders Kristoffersson

Consultant

  • Ph.D in Pharmaceutical Biosciences and M.Sc in Molecular Biotechnology Engineering
  • Post doc with Hoffman-La Roche providing modelling and simulation in support of a new β-lactamase inhibitor
  • Research experience in pharmacometrics includes:
    • Clinical trial design
    • Population PK/PD modeling and simulation
    • Development of a framework for model based PK/PD modeling framework for antibiotic dose selection
  • Link to Anders Kristoffersson’s publications
Dr. Andrew Hooker, Advisor

Dr. Andrew Hooker

Advisor

  • Ph.D. in Bioengineering, M.Sc. in Bioengineering, B.S. in Physics (Minor in Mathematics)
  • Associate professor at the Pharmacometric Research Group, Uppsala University
  • Degrees from University of Colorado, University of Washington (Seattle, USA), followed by post-doc at Uppsala University (Sweden).
  • Research ranges between methodological and applied pharmacometrics
    • Optimal experimental design
    • Methodological problems associated with building and evaluating Pharmacometric models
    • (Repeated) time-to-event model building
    • Development and use of PKPD models
    • Therapeutic areas include cancer, addiction, PET, biologics, etc.
  • Co-developer of a number of software programs including Xpose 4PsN, and the optimal design program PopED
  • 11 years experience as a consultant to pharmaceutical industry, including support and regulatory interactions leading to successful filings for new drug applications in Europe and the US
  • Link to Andrew Hooker’s publications

Dr. Angela Äbelö

Consultant

  • Ph.D. in Pharmacokinetics and Drug Therapy and M.Sc. in Pharmaceutical Sciences
  • Experience in pharmacokinetics and PKPD-modelling across several phases in drug development
  • Experience as Senior Lecturer and Associate Professor in Pharmacokinetics and Pharmacodynamics, Gothenburg University, years 2010-2017
  • Experience as Consultant at Exprimo NV
  • Link to Angela Äbelö’s publications
Antonio Klaric, Analyst Consultant, System Administrator

Antonio Klaric

Analyst Consultant, System Administrator

  • B.Sc in Computer Engineering at Zagreb Polytechnic for Technical Sciences
  • Work as linux system administrator at Styria IT, providing support to developers and managing Linux servers
Dr. Ari Brekkan, Consultant

Dr. Ari Brekkan

Consultant

  • Ph.D in Pharmaceutical Biosciences and M.Sc in Drug Discovery and Development
  • Research experience in pharmacometrics includes:
    • Population PK and PKPD modeling and simulation with a focus on biological medicinal products displaying target-mediated drug disposition
    • Modeling underlying variables using hidden-Markov models
    • Investigating sampling strategies for model-based dose individualization of coagulation factors
    • Clinical trial (optimal) design
  • Link to Ari Brekkan’s Publications
Arnaud Gaby, Associate Consultant, Data Programmer

Arnaud Gaby

Associate Consultant, Data Programmer

  • B.Sc in Statistics and Computing
  • Experience as a Principal Statistical Programmer in Pharmacometrics from Novartis
  • Experience as a Biostatistician
Arnaud Pharasyn, Senior Consultant, IT Manager

Arnaud Pharasyn

Senior Consultant, IT Manager

  • M.Sc. in Physics from the Ecole Normale Supérieure de Lyon
  • Experience as Consultant in the IT sector
  • Expertise in Software Development and Data Processing within Astrophysics, Electronics, Gaming industry, and Geophysics
  • Involved in the IT support to the personnel and students at the Geophysics department of Uppsala University
  • Responsible during more than 3 years for the maintenance of the IT infrastructure at the Swedish National Seismic Network
Dr. Celine Sarr, Senior Consultant

Dr. Celine Sarr

Senior Consultant

  • Ph.D. in Pharmaceutical Biosciences, M.Sc. in Biostatistics and Pharm.D.
  • Hospital Residency
  • Experience as Senior Consultant at Exprimo NV, as Senior expert modeler and cluster leader in the Modeling and Simulation group at Novartis:
    • Population PK/PD modelling and simulation e.g. Oncology
    • Project team, internal decision and submission support
    • Portfolio and operational management
  • DDMoRe scientific coordinator and product lead of the model repository
  • Link to Celine Sarr’s publications
Dr. Chayan Acharya, Senior Consultant

Dr. Chayan Acharya

Senior Consultant

  • Ph.D. in Pharmaceutical Sciences, M.Sc. in Physics, B.Sc. in Physics (Minor in Mathematics and Chemistry)
  • Former Postdoctoral Fellow at Uppsala University in Pharmacometrics research group
  • Research experience in Pharmacometrics includes:
    • Population PK/PD modeling and simulation and optimization of clinical trials
    • Developer of an R-package for population pharmacokinetic model diagnosis using non-compartmental analysis metrics
  • Therapeutic areas include immunosuppressant and pain management
  • Link to Chayan Acharya’s publications
Dr. Daniel Röshammar, Senior Consultant

Dr. Daniel Röshammar

Senior Consultant

  • Ph.D. in Medical Sciences, M.Sc. in Pharmaceutical Sciences
  • Experience as Managing Director of SGS Exprimo, Senior Pharmacometrician and Section Director at AstraZeneca, and Modelling and simulation Expert at Ferring Pharmaceuticals
    • Experience in when and how to apply pharmacometrics across different stages of clinical drug development, for influencing internal and regulatory decisions
    • Contribution to the filing of new drug applications, and experience with regulatory interactions
    • Project portfolio and team management
    • Therapeutic areas include infectious diseases, cardiovascular, respiratory, urology, oncology, intensive care, and reproductive health
  • Link to Daniel Röshammar’s publications
Dr. Elin Matsson, Senior Consultant

Dr. Elin Matsson

Senior Consultant

  • PhD. in Biopharmaceutics and M.Sc. in Pharmaceutical Sciences.
  • Pharmacokinetics Assessor at the Swedish Medical Products Agency.
    • Scientific assessment of the clinical pharmacology package of new drug applications with a special focus on drug absorption, drug-drug interactions, drug transporters and PBPK models.
    • Scientific advice and contributing to regulatory guidelines.
  • Fellow at the Division of Quantitative Methods and Modeling (DQMM), Office of Research and Standards (ORS), Office of Generic Drugs (OGD), CDER, FDA.
    • Working in the PBPK and quantitative clinical pharmacology teams in projects supporting regulatory decision making, for example concerning narrow therapeutic index drugs and pediatric bioequivalence.
    • Contributing to product-specific guidances for generic drug development.
  • Link to Elin Matsson’s publications
Dr. Elodie Plan, Principal Consultant, Board Member

Dr. Elodie Plan

Principal Consultant, Board Member

  • Ph.D. in Pharmaceutical Biosciences, M.Sc. in Biostatistics and Pharm.D.
  • Research focus on investigating pharmacometric methods and developing novel models for discrete data
    • Therapeutic areas include Neurosciences -epilepsy, Alzheimer’s, pain, migraine, Parkinson’s, schiziophrenia-, Gastroenterology, and Women’s Health -endometriosis, uterine contractility-
    • Methodologies involve Markov models, time-varying hazards models, and repeated time-to-categorical events models
  • Experience as a Visiting Scientist, member of the Systems Biology group, at the contracting company Metrum Research Group, CT, USA
    • Development in a Bayesian framework of a semi-mechanistic model component predicting fracture rate in bone-related diseases
    • Support in consulting work -contribution to proposals, writing of reports, technical advices and pharmacometric analyses-
  • Pharmacometric tutoring performed at several workshops
  • Pharmacokinetic-pharmacodynamic modelling executed in collaboration with different pharmaceutical companies
  • Link to Elodie Plan’s publications

Emma Ångström

Chief Financial Officer

  • B.Sc. in Business Administration and Economics from Uppsala University
  • Experience of working within finance and control since 1997, including positions as:
    • Auditor at PwC
    • Production Controller at Fresenius Kabi
    • Manager within Finance and Controlling at the Swedish Medical Products Agency
Dr. Emma Hansson, Senior Consultant

Dr. Emma Hansson

Senior Consultant

  • Ph.D in Pharmaceutical Biosciences and M.Sc in Pharmacy
  • Research experience in pharmacometrics includes:
    • Population PK/PD modeling and simulation in oncology
    • Development of an overarching PK/PD modeling framework in oncology, linking exposure, longitudinal biomarkers, adverse effects and treatment outcome
  • Pharmacometric tutoring performed at several workshops
  • Pharmacokinetic & Pharmacometric assessor at the Swedish Medical Products Agency
    • Scientific assessment of clinical pharmacology aspects, especially population PK and PK/PD analyses, as part of regulatory evaluation of Marketing Authorization Applications
    • Member of the expert group on modelling and simulation at the European Medicines Agency
    • Therapy areas covered include e.g. oncology, endocrinology and infectious diseases
  • Link to Emma Hansson’s publications

Dr. Enrica Mezzalana

Consultant

  • PhD. in Bioengineering and Bioinformatics and M.Sc. in Bioengineering
  • Experience as Modeling and Simulation scientist at Exprimo NV and as Clinical Pharmacology and Pharmacometrics scientist at Menarini:
    • Population PK/PD modelling and simulation (e.g. Oncology and Pain)
    • Mechanistic physiologically based modelling (PBPK), primarily applied to DDI predictions
    • Project team, internal decision and submission support
    • Experience with small and large molecules
Eric Sandström, Analyst Consultant, Systems Developer

Eric Sandström

Analyst Consultant, Systems Developer

  • M.Sc. in Biotechnology Engineering from Uppsala University.
  • Experience in software development.
Dr. Erik Sjögren, Senior Consultant

Dr. Erik Sjögren

Senior Consultant

  • Ph.D. in Pharmaceutics, M.Sc. in Pharmaceutical Sciences
  • Associate Professor in Biopharmaceutics at the Department of Pharmacy, Uppsala University
  • Post doc, absorption model development, at AstraZeneca, Mölndal, Sweden
  • Long research experience of applying mechanistic physiologically based modelling in areas such as:
    • Pharmacokinetics (PBPK)
    • Biopharmaceutics (PBBP and Drug delivery)
    • Intestinal absorption (mechanistic absorption modelling)
    • Hepatic disposition (transporters and enzymes)
  • Research in a wide scope of academic projects including supervision of Ph.D. students.
  • Experience as an external biopharmaceutical consultant to drug development companies including in silico model based support.
  • Link to Erik Sjögren’s publications

Fredrik Alpsten

Board Member

  • Holds a Master of Science degree from Stockholm School of Economics.
  • 25 years of operational, financial and strategic business experience as an executive in the life science field.
  • Has served as Senior Vice President and CFO of Boule Diagnostics AB, a Swedish publicly-traded diagnostics company and CFO and Deputy CEO of IRRAS AB, a Swedish listed med-tech company. Currently he serves as CFO of AlgiPharma AS, a Scandinavian biopharmaceutical company.
  • He has also served as President CEO of Doxa AB, a Swedish listed med-tech company and President CEO of Clinical Diagnostic Solutions Inc., a US diagnostic company.
  • He currently serves as Chairman of the Board of Personlig Almanacka Nordic AB and Vice Chairman and Chairman of the audit committee of Binero Group AB (listed at Nasdaq).
Georges Etté, Associate Consultant, Data Programmer

Georges Etté

Associate Consultant, Data Programmer

  • M.Sc. in Mathematics/Statistics from Pierre et Marie Curie University in Paris
  • Worked 10 years in data programming for pharmacometrics in the pharmaceutical industry
  • Worked 5 years in data programming for clinical trial reporting in the pharmaceutical industry
  • Worked 5 years in biostatistics in a Contract Research Organisation
  • Experience in software development
Dr. Giovanni Smania, Consultant

Dr. Giovanni Smania

Consultant

  • Ph.D. in Bioengineering and Bioinformatics and M.Sc. in Bioengineering
  • Experience as Clinical Pharmacology and Pharmacometrics scientist at Menarini
    • Translational and clinical population PK/PD modeling (e.g. Oncology and Pain)
    • Experience with small and large molecules
    • Project team, internal decision and submission support
  •  Link to Giovanni Smania’s publications

Dr. Ida Netterberg

Consultant

  • Ph.D in Pharmaceutical Sciences and a M.Sc in Pharmacy
  • Research experience in pharmacometrics includes:
    • Population PKPD modeling and simulation with a focus in oncology (chemotherapy and cancer immunotherapy)
    • Modeling adverse events, e.g. chemotherapy induced myelosuppression and febrile nutropenia
    • Modeling changes in tumor size and circulating biomarkers and overall survival
  • Link to Ida Netterberg’s publications
Dr. Jakob Ribbing, Senior Consultant

Dr. Jakob Ribbing

Senior Consultant

  • Ph.D. in Biopharmaceutical Sciences and M.Sc. in Pharmacy
  • Extensive experience as the Pfizer pharmacometrics subject-matter expert on Allergy and Respiratory disease (e.g. COPD, Asthma and Allergic Rhinitis)
  • Many applications of non-linear mixed effects modeling, to both individual-level (internal-trial) and aggregate level (literature-summary-level) data
  • Numerous applications of modeling for:
    • Setting target/hurdles for interim, trial or program continuation, or PoP/PoM/PoC declaration and transition
    • Making decisions on interim, trial or program continuation, or PoP/PoM/PoC declaration and transition, as well as dose/regimen selection, in various phases
    • Translation across populations and endpoints
    • Pharmacoeconomic simulations of real-life outcomes
  • Link to Jakob Ribbing’s publications
Dr. Joakim Nyberg, Principal Consultant

Dr. Joakim Nyberg

Principal Consultant

  • Ph.D. in Pharmaceutical Biosciences and M.Sc. in Engineering Physics
  • Experience in system development and project management mainly with high security systems
  • Research focus on practical and methodological optimal design
    • Primary developer of the optimal design tool PopED
    • Worked with estimation methods for Pharmacometric models
    • Therapeutic areas include diabetes, oncology, immunosuppressant and QT-prolongations
  • Team leader for a large phase III study, involving project management, QA/QC processes and data security
  • Link to Joakim Nyberg’s publications
Dr. Jurgen Langenhorst, Associate Consultant

Dr. Jurgen Langenhorst

Associate Consultant

  • Ph.D in Pharmaceutics and M.Sc Pharmacy.
  • Research experience in pharmacometrics includes
    • Population PK/PD modeling and simulation of chemotherapeutic drugs in pediatrics and adults.
    • Time-to-event modelling of composite and competing end-points.
    • Development of a PK/PD framework for design of trials evaluating optimal dosing in conditioning regimens prior to allogeneic cell transplantation.
    • Modelling immune reconstitution after allogeneic cell transplantation.
    • Communicating results to medical professionals without pharmacometric background.
Dr. Kajsa Harling, Consultant, Systems Development

Dr. Kajsa Harling

Consultant, Systems Development

  • Ph.D. in Scientific Computing and M.Sc. in Biotechnology Engineering from Uppsala University
  • Expertise in software development for pharmacometric modelling
  • Developer of PsN
  • Experience in algorithm development, numerical optimization and high performance computing
Prof. Lena Friberg, Advisor

Prof. Lena Friberg

Advisor

  • Ph.D. in Pharmacokinetics and Drug Therapy and M.Sc. in Pharmaceutical Sciences
  • Professor in Pharmacometrics at the Pharmacometric Research Group, Uppsala University
  • Research focus on development of population PK and PD models for desired effects and adverse events
    • Therapeutic areas include bacterial infections, oncology, schizophrenia, rheumatoid arthritis, and QT-prolongation
    • Model-based translation of in vitro and animal PKPD to patients, and predictions from early to late phase development
  • Consultant to pharmaceutical industry:
  • Performed and advised on a wide range of PK and PKPD-modeling projects within bacterial and fungi infections, septic shock, endocrinology, oncology, rheumatoid arthritis, multiple sclerosis, schizophrenia, QT-prolongation and arrhythmia
  • Several of these projects have directly supported filing and interactions with EMA and FDA
  • Link to Lena Friberg’s publications
Dr. Marcus Björnsson, Senior Consultant

Dr. Marcus Björnsson

Senior Consultant

  • Ph.D. in Pharmacokinetics and Drug Therapy and M.Sc. in Pharmaceutical Sciences
  • Experience as Senior Clinical Pharmacometrician and Neuroscience Therapy Area Pharmacometrics Expert at AstraZeneca
    • Population PK/PD modeling and simulation in a large number of drug development projects
    • Modeling of informative dropout
    • Experience from all phases of clinical drug development
  • Link to Marcus Björnsson’s publications

Marie Karlsson

Project Coordinator

Long experience in software development and maintenance of HR and payroll applications:

  • Manager for several software development teams
  • Senior project manager and scrum master
  • Monitoring data processing
  • Requirements and testing
  • Customer support and training
  • Administration
Dr. Marie Sandström, Chief Operations Officer, Deputy CEO

Dr. Marie Sandström

Chief Operations Officer, Deputy CEO

  • Ph.D. in Pharmacokinetics and Drug Therapy and M.Sc. in Pharmaceutical Sciences
  • Experience as Lecturer and Associate Professor in Pharmacokinetics and Drug Therapy, Uppsala University, years 1997-2003
  • Experience in all clinical phases of Drug Development from AstraZeneca, years 2003-2013, as:
    • Clinical Pharmacometrician / Pharmacokineticist
    • Head of Clinical Pharmacology in Södertälje
    • Clinical Pharmacology & DMPK Projects Director in the therapeutic area of  Neuroscience
    • Global Director Clinical Pharmacometrics
  • Link to Marie Sandström’s publications
Markus Seltmann, Analyst Consultant, Systems Architecture

Markus Seltmann

Analyst Consultant, System Administrator

  • Computer Science studies at TU Dresden and HTW Dresden
  • Brief work in webdesign for Eurojobcenter Dresden
  • Training as an IT Specialist at TU Dortmund
  • Work as a System Administrator at the IT Department of the TU Dortmund
Dr. Martin Bergstrand, Principal Consultant, Board Member

Dr. Martin Bergstrand

Principal Consultant, Board Member

  • Ph.D. in Pharmaceutical Biosciences and M.Sc. in Biomedicine
  • Experience as clinical pharmacology research scientist at AstraZeneca R&D, Mölndal, Sweden Focus on phase I and II drug development within the field of metabolic disorders, e.g. diabetes.
    • Clinical drug development in phase I and II trials with multiple drug candidates ranging across several mechanisms of action
  • Extensive experience with mechanism based population PK modeling including complex absorption, non-linear elimination, enzyme induction and metabolite kinetics
  • Pharmacodynamic modeling in areas such as: Type II diabetes, Infectious disease, SLE (Lupus) and Oncology
  • Experience as contract researcher on behalf of several pharmaceutical companies
  • Link to Martin Bergstrand’s publications
Dr. Martin Fransson, Consultant

Dr. Martin Fransson

Consultant

  • Ph.D. in Medical Science and M.Sc. in Applied Physics and Electrical Engineering
  • Experience as Consultant of modeling and simulation in pharmacokinetics
  • Postdoctoral research in toxicokinetics
  • Research has focused on
    • Population PK modeling of anticancer drugs
    • PBPK modeling of heavy metals
  • Team leader and coordinator for IT work packages in European and Swedish infrastructure projects for biobanks, including project management, design of use-cases and information models for biobank databases
  • Link to Martin Fransson’s publications

Prof. Mats Karlsson

Board Chair, Advisor

  • Ph.D. in Pharmacokinetics and M.Sc. in Pharmaceutical Sciences
  • Professor of Pharmacometrics at the Pharmacometric Research Group, Uppsala University
  • Research focus on methodological development and application of pharmacometrics to drug development and drug usage
    • Leads a research group with >40 scientists, successfully supervised 35 students to their PhD, mentored >30 postdocs, published 250 peer-reviewed full-length research articles and is co-developer of 3 widely used pharmacometric software
  • Served as consultant to pharmaceutical industry for 20 years, and contributed with pharmacometric analyses to >20 successful filings for new drug applications in Europe and the US
  • Link to Mats Karlsson’s publications
Dr. Mats Magnusson, Principal Consultant

Dr. Mats Magnusson

Principal Consultant

  • Ph.D. in Pharmaceutical Biosciences and M.Sc. in Pharmaceutical Sciences
  • Experience as Senior Consultant at Exprimo NV, and as Visiting Scientist of the Pharmacometrics groups at Pfizer:
    • Population PK/PD modelling, simulation and optimization of trials in paediatric populations
    • Mechanistic modelling of monoclonal antibodies
    • Benefit-risk assessment
    • Developer of methodology to manage large pharmacometric projects with critical timelines
    • Link to Mats Magnusson’s publications
Dr. Moustafa Ibrahim, Associate Consultant

Dr. Moustafa Ibrahim

Associate Consultant

  • Ph.D in Pharmaceutical Biosciences and M.Sc in Clinical Pharmacy.
  • Research experience in pharmacometrics includes:
    • Population PK/PD modeling and simulation.
    • Development of fast and robust novel methodologies through model-proxy analysis for automated model building and model evaluation.
    • Model-based analysis of competing risks with interval-censored data.
    • Optimal design of clinical trials for anticipated drug effects and clinical status assessment.
  • Link to Moustafa’s publications.
Dr. Niclas Jonsson, Principal Consultant

Dr. Niclas Jonsson

Principal Consultant

  • Ph.D. in Pharmaceutical Biosciences and M.Sc. in Pharmaceutical Sciences
  • Associate Professor of Pharmacometrics at the Pharmacometrics Research group, Uppsala University
  • Experience as Senior Consultant at Exprimo NV and as Global Head of Modeling & Simulation at Roche:
    • Pharmacometric project management
    • Population PKPD modelling and simulation expert
    • Developer of methodology to manage large pharmacometric projects with critical time lines
  • Original developer of the software programs Xpose 4 and PsN
  • Link to Niclas Jonsson’s publications

Dr. Ola Caster

Associate Consultant

  • Ph.D. in Computer and Systems Sciences, M.Sc. in Mathematical Statistics and Pharmacy
  • More than 10 years’ research experience from developing and applying statistical methods in large post-marketing data sets to detect and analyze adverse effects from medicines
  • Research and method development in the application of decision analysis for benefit-risk assessment of medicines
  • Experience from software development
  • Link to Ola Caster’s publications
Per Lundström, Administrative Assistant

Per Lundström

Administrative Assistant

  • B.Sc in Behavioral Sciences at Uppsala University
  • Experience within administration, advertising and graphical design.
Dr. Peter Milligan, Chief Executive Officer

Dr. Peter Milligan

Chief Executive Officer

  • Ph.D. in Medicine and Therapeutics and M.Sc. in Clinical Pharmacy
  • Joined Pfizer in 1994 with a responsibility to initiate and implement Population PK, which evolved to become Pharmacometrics.
  • Spent 2003 working with Pfizer discovery colleagues to initiate, develop and formalize discovery based Pharmacometric activities and increase awareness of model informed methods.
  • From 2005 on, led model informed drug development (MIDD) implementation across Pfizer, on behalf of Global Clinical Pharmacology. MIDD has been widely adopted to develop integrated analyses of relevant data to inform strategy, design and decision making in drug discovery and development. MIDD components have also been incorporated into global regulatory submissions for numerous Pfizer products.
  • Became Global Head of Pharmacometrics, Vice President, and member of  Global Clinical Pharmacology Leadership Team in 2007. Responsible for managing, formalizing, coordinating internal and outsourced MIDD activities for Global Clinical Pharmacology across Pfizer enterprise. Responsible for 40 ±5 FTEs located at sites in the USA, EU and Asia. Responsible for budget supporting outsourcing and academic interactions.
  • Has collaborated extensively with discipline experts within Pfizer and across the Pharmaceutical Industry as a whole (including Regulatory Agency staff). Has supported and maintained collaborations with academics from leading centres worldwide (over 40 PhD and/or Postdocs).  Areas of collaboration include Pharmacometrics (MIDD), Pharmacokinetics, Pharmacoeconomics, Statistics, Clinical , Pre-Clinical Pharmacology and Drug Safety.
  • Provided broader Clinical Pharmacology support for compounds in drug discovery and development (A&R, Gastrointestinal, Cardiovascular, Neuroscience, Sexual Health, anti-viral) necessitating frequent compound/product related visits to Health Authorities.
  • Link to Peter Milligan’s publications.
Dr. Peteris Prusis, Associate Consultant, Data Programmer

Dr. Peteris Prusis

Associate Consultant, Data Programmer

  • PhD in Pharmaceutical Biosciences.
  • Experience in molecular modeling for drug discovery at Orion.
  • Experience in using machine learning techniques for ADMET property modeling ( AstraZeneca).
  • Discovery and development of proteochemometrics (Uppsala university).
  • Link to Peteris Prusis’s publications.

Dr. Qing Xi Ooi

Associate Consultant

  • PhD. in pharmacometrics
  • Research experience in pharmacometrics includes:
    • Population PKPD modelling and simulation
    • Special interest in kinetic-pharmacodynamic modelling (modelling PD endpoint in absence of PK data) and joint modelling (modelling multiple PK and/or PD endpoints simultaneously)
    • Quantitative systems pharmacology
  • Link to Qing Xi’s publications 
Richard Anziano, Principal Consultant, Chief Statistician

Richard Anziano

Principal Consultant, Chief Statistician

  • M.Sc. in Statistics
  • Formerly Global Head of Statistics and Chief Statistician for Pfizer Inc. with responsibility for approximately 250 statisticians and a budget of $50M
  • Fostered a culture of collaboration across statisticians, clinical pharmacologists, and clinicians to enable and deliver MIDD
  • Led quantitative assessment of late stage probabilities of technical and regulatory success through modeling and simulation for all late-stage assets compared to industry/therapeutic area benchmarks
  • Member of cross PhRMA statistics group, led collaborations delivering such things as Data Monitoring Committee member training
  • Quantitatively assessed more than 50 potential external business development assets
  • Over 25 years of drug development experience in Neuroscience, Pain, Cardiovascular, Infectious Disease, Rare Disease
  • Link to Richard’s Publications
Dr. Robin Svensson, Associate Consultant

Dr. Robin Svensson

Associate Consultant

  • PhD in Pharmaceutical Biosciences
  • Research experience in pharmacometrics includes:
    • Population PK-PKPD modeling and simulation for clinical and semi-mechanistic tuberculosis models
    • Clinical trial simulations to aid decision-making and design of future studies
    • Time-to-event modelling including simultaneous analysis of continuous and time-to-event data
    • Development of a framework for model-based individualized dose optimization
    • Covariate modelling using the full random effects model (FREM) methodology
  • Link to Robin’s publications
Dr. Sofia Friberg Hietala, Senior Consultant

Dr. Sofia Friberg Hietala

Senior Consultant

  • Ph.D. in Pharmacology and M.Sc. in Pharmacy
  • Experience as Senior Clinical Pharmacometrician at AstraZeneca
    • Pharmacokinetic/pharmacodynamic analyses in studies across all phases of clinical drug development
  • Pharmacokinetics and Pharmacometrics Assessor at the Swedish Medical Products Agency
    • Scientific assessment of marketing authorization applications, specifically regarding dose-finding, ADME properties, drug-drug interactions and special populations
    • Scientific advice and normative work (contributing to regulatory guidelines)
    • Former Vice-Chairperson of the Modelling and Simulation Working Group at the European Medicines Agency
  • Link to Sofia Friberg Hietala’s publications
Svetlana Freiberga, Associate Consultant, Data Programmer

Svetlana Freiberga

Associate Consultant, Data Programmer

  • B.Sc. in Mathematics and Pedagogy from University of Latvia
  • Experience in software development and automated report generation for PsN
  • Experience as a teacher of mathematics

Dr. Tobias Kanacher

Senior Consultant

  • PhD. in pharmaceutical biochemistry.
  • Experience as Consultant PBPK Modelling and Simulation at SGS Exprimo and Systems Pharmacology Expert at Bayer
    • Advice preclinical and clinical drug development teams how to apply PBPK modelling across different stages of clinical drug development, for advancing small and large molecules
    • Contribution to the filing of new drug applications, and experience with regulatory interactions
    • Experience in when and how to apply PBPK modelling across different stages of clinical drug development, for influencing internal and regulatory decisions
    • Therapeutic areas include oncology, women’s health, cardiovascular diseases, inflammatory diseases, hematology, pain and ophthalmology
  • Experience as DMPK project representative, PBPK Expert and Laboratory team leader at Takeda, Nycomed and Altana Pharma
    • Consulting clinical drug development teams as Expert for ADME and physiology based pharmacokinetic (PBPK) modelling
    • Development of in vitro ADME and immunological assays with HPLC/UV-Vis, LC/MSMS, radioactive tracer or flow cytometry detection
  • Link to Tobias Kanacher’s publications
Prof. Ulrika Simonsson, Advisor

Prof. Ulrika Simonsson

Advisor

  • Ph.D. in Pharmaceutical Biosciences and M.Sc. in Pharmaceutical Sciences
  • Professor at the Pharmacometric Research Group, Uppsala University
  • Experience as post doc with Pharsight Corporation, CA, USA and as a pharmacometrician at AstraZeneca, Mölndal, Sweden
  • Research focus on how modelling and simulation of PK and PD can be used to optimize drug development and the link to personalized medicine
    • Was during 2012-2017  leading the modelling and simulation work within the European IMI funded consortium Predict-TB focusing on translation of pre-clinical to clinical of anti-tuberculosis drugs
  • More than 20 years of experience as a pharmacometric external consultant to drug development companies including regulatory interactions and filing
    • Patent pending for dosing nomograms based on Ulrika’s consultancy work
  • Therapeutic areas include tuberculosis, malaria, HIV, thrombosis/cardiovascular diseases, diabetes, insomnia, prostate cancer, hypertension, asthma and cortisol insufficiency
  • Link to Ulrika Simonsson’s publications